Belite Bio (BLTE) Aperçu de l'action
Belite Bio, Inc, une société biopharmaceutique de développement de médicaments au stade clinique, se consacre à la recherche et au développement de nouvelles thérapies répondant à des besoins médicaux non satisfaits aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
BLTE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Belite Bio, Inc Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$183.16 |
| Plus haut sur 52 semaines | US$200.00 |
| Plus bas sur 52 semaines | US$64.80 |
| Bêta | -1.24 |
| Variation sur 1 mois | 9.51% |
| Variation sur 3 mois | 33.84% |
| Variation sur 1 an | 176.38% |
| Variation sur 3 ans | 493.71% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | 1,629.56% |
Nouvelles et mises à jour récentes
Belite Bio On Track For A Potential Blockbuster Launch In 2027
Summary Belite Bio has stayed on track toward a potential blockbuster launch of tinlarebant in 2027, with FDA approval for STGD1 expected in February 2027. The FDA's acceptance of the NDA and priority review status reduce (but don't eliminate) regulatory risks, while label scope and pricing remain key unknowns. Management is planning to launch tinlarebant with a modest 50-rep sales force, but driving awareness among patients and general optometrists and ophthalmologists will be key over the long term. My base-case assumptions lead me to a fair value between $205 and $220, but a clean FDA approval with generous labeling and pricing meaningfully above $350K/year could drive significant upside. With $780M in cash and manageable burn, BLTE is a 'strong hold'—I would revisit it on a sentiment-driven pullback. Read the full article on Seeking Alpha
BLTE: Priority Review For Stargardt Therapy Will Shape Multi Blockbuster Potential
Belite Bio's analyst price target has moved higher from $211.50 to about $223.89 as analysts factor in recent target increases from several firms and renewed enthusiasm around tinlarebant following the FDA's acceptance of the NDA submission and long term U.S. sales potential modeled in recent research. Analyst Commentary Recent Street research on Belite Bio focuses heavily on the potential of tinlarebant, the valuation impact of higher long term sales assumptions and the execution risk around regulatory and commercial milestones in the U.S. Bullish Takeaways Bullish analysts highlight tinlarebant as a first therapeutic candidate to show a statistically significant reduction in lesion growth for Stargardt disease, which they see as a core driver for Belite Bio's long term revenue potential.Recent updates
Belite Bio On Track For A Potential Blockbuster Launch In 2027
Summary Belite Bio has stayed on track toward a potential blockbuster launch of tinlarebant in 2027, with FDA approval for STGD1 expected in February 2027. The FDA's acceptance of the NDA and priority review status reduce (but don't eliminate) regulatory risks, while label scope and pricing remain key unknowns. Management is planning to launch tinlarebant with a modest 50-rep sales force, but driving awareness among patients and general optometrists and ophthalmologists will be key over the long term. My base-case assumptions lead me to a fair value between $205 and $220, but a clean FDA approval with generous labeling and pricing meaningfully above $350K/year could drive significant upside. With $780M in cash and manageable burn, BLTE is a 'strong hold'—I would revisit it on a sentiment-driven pullback. Read the full article on Seeking AlphaBLTE: Priority Review For Stargardt Therapy Will Shape Multi Blockbuster Potential
Belite Bio's analyst price target has moved higher from $211.50 to about $223.89 as analysts factor in recent target increases from several firms and renewed enthusiasm around tinlarebant following the FDA's acceptance of the NDA submission and long term U.S. sales potential modeled in recent research. Analyst Commentary Recent Street research on Belite Bio focuses heavily on the potential of tinlarebant, the valuation impact of higher long term sales assumptions and the execution risk around regulatory and commercial milestones in the U.S. Bullish Takeaways Bullish analysts highlight tinlarebant as a first therapeutic candidate to show a statistically significant reduction in lesion growth for Stargardt disease, which they see as a core driver for Belite Bio's long term revenue potential.
Single-Drug Dependence And Delayed Trials Will Shape Future Retinal Therapy Prospects
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on therapies for retinal diseases such as Stargardt disease and geographic atrophy. What are the underlying business or industry changes driving this perspective?Belite Bio (BLTE) Stock Could Be 35% Undervalued After Tinlarebant NDA Submission
Why Belite Bio Stock Is Back in Focus After Tinlarebant NDA Milestone Belite Bio (BLTE) is drawing attention after completing its rolling New Drug Application submission to the FDA for tinlarebant, an oral therapy candidate for Stargardt disease type 1, a rare inherited retinal condition with no approved treatments. See our latest analysis for Belite Bio. Belite Bio’s latest regulatory milestone comes after a period where momentum has cooled in the share price, with the stock down 14.35% on a...Oral Retinal Therapy Potential Will Reshape Long Term Outlook For This Pre Revenue Biotech
Catalysts About Belite Bio Belite Bio is a clinical stage biopharmaceutical company focused on oral therapies for retinal and liver diseases. What are the underlying business or industry changes driving this perspective?Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Belite Bio (NASDAQ:BLTE) is off 21% in Monday trading after reporting disappointing phase 2 results on tinlarebant for adolescent Stargardt Disease, a rare eye disease characterized by fatty material build-up in the macula. While the company presented the results in a positive light in a Friday evening news release -- a majority of the subjects showed stabilization of visual acuity in at least one eye and no atrophic lesion in 12 of 13 subjects over 12 months of treatment, investors seem less than impressed. Data also showed that fundus autofluorescence imaging indicated no autofluorescence expansion in 7 of 13 participants and 9 of 13 subjects demonstrated a stabilization or improvement in visual acuity. The trial is slated to last for two years.Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Belite Bio (NASDAQ:BLTE) said on Friday it had received approval from the National Medical Products Administration of China to begin the Phase 3 trial of its drug, LBS-008, in adolescent with a rare type of eye disease called Stargardt disease STGD1. A 2-year Phase 2 trial in adolescent STGD1 and a global Phase 3 trial in adolescent STGD1 are ongoing. A Phase 3 trial, dubbed dragon, to Evaluate the Safety and Efficacy of LBS-008 in adolescent subjects had begun in the U.S., the United Kingdom, Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia, with several patients already enrolled.Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Recently IPO’d Belite Bio, Inc (NASDAQ:BLTE) ended a four-day selloff on Monday to climb ~15% after the biopharma company announced the enrollments of its pivotal U.S. Phase 3 clinical trial for lead candidate LBS-008 in patients with eye disorder Stargardt Disease (STGD1). STGD1 has no FDA-approved therapies, and it is the commonest inherited retinal dystrophy that can lead to blurring and/or loss of central vision. LBS-008, an orally administered tablet, is currently undergoing a 2-year Phase 2 trial and a 2-year Phase 3 (DRAGON) trial involving adolescents with STGD1. The company plans to enroll about 60 subjects in the Phase 3 trial which is currently underway in the U.S., U.K., Germany, Belgium, Switzerland, Hong Kong, Taiwan, and Australia. In Q4 2022, BLTE expects to launch a Phase 2/3 trial designed to evaluate the potential of LBS-008 in non-neovascular age-related macular degeneration (Dry AMD), another eye condition with no FDA-approved therapies. Read more about BLTE’s upcoming milestones.Belite Bio GAAP EPS of -$0.23 beats by $0.05
Belite Bio press release (NASDAQ:BLTE): 1H GAAP EPS of -$0.23 beats by $0.05. As of June 30, 2022, the company had $48.7M in cash.Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Belite Bio (NASDAQ:BLTE) on Tuesday said it had submitted an investigational new drug application to the U.S. FDA to proceed with its phase 3 trial of its oral tablet LBS-008 for the treatment of Stargardt disease (STGD1). STGD1 is a rare genetic eye disease that is characterized by fatty material build up on the macula. Belite Bio (BLTE) said it is currently conducting a 2-year phase 2 trial and a 2-year phase 3 trial of LBS-008 in adolescent STGD1 subjects. The company said its phase 3 trial, called DRAGON, had already been approved for enrollment in the UK, Switzerland, Hong Kong, Taiwan and Australia. U.S.-listed shares of BLTE earlier closed +5.3% at $43.70.Rendement pour les actionnaires
| BLTE | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | 14.0% | -3.0% | -0.2% |
| 1Y | 176.4% | 45.8% | 14.8% |
Rendement vs Industrie: BLTE a dépassé le secteur US Pharmaceuticals qui a rapporté 45.8 % au cours de l'année écoulée.
Rendement vs marché: BLTE a dépassé le marché US qui a rapporté 14.8 % au cours de l'année écoulée.
Volatilité des prix
| BLTE volatility | |
|---|---|
| BLTE Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Cours de l'action stable: BLTE n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de BLTE ( 8% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2016 | 41 | Tom Lin | www.belitebio.com |
Belite Bio, Inc, une société biopharmaceutique de développement de médicaments en phase clinique, se consacre à la recherche et au développement de nouvelles thérapies répondant à des besoins médicaux non satisfaits aux États-Unis. Son principal produit candidat est le Tinlarebant (LBS-008), un médicament administré par voie orale, qui fait l'objet d'un essai clinique de phase 3 en tant qu'intervention précoce pour le maintien de la santé et de l'intégrité des tissus rétiniens chez les patients atteints de la maladie de Stargardt de type 1 et d'atrophie géographique. La société développe également LBS-009, une thérapie orale de la protéine de liaison du rétinol 4, qui est en cours de développement préclinique pour les maladies du foie, y compris la stéatose hépatique non alcoolique, la stéatohépatite non alcoolique, le diabète de type 2, ainsi que la goutte.
Belite Bio, Inc Résumé des fondamentaux
| BLTE statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$7.77b |
| Bénéfices(TTM) | -US$102.36m |
| Recettes(TTM) | n/a |
Le site BLTE est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| BLTE compte de résultat (TTM) | |
|---|---|
| Recettes | US$0 |
| Coût des recettes | US$0 |
| Marge brute | US$0 |
| Autres dépenses | US$102.36m |
| Les revenus | -US$102.36m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.54 |
| Marge brute | 0.00% |
| Marge bénéficiaire nette | 0.00% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de BLTE?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/09 19:50 |
| Cours de l'action en fin de journée | 2026/09/09 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Belite Bio, Inc est couverte par 12 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |
| Steven Seedhouse | Cantor Fitzgerald & Co. |